Careers  |  Sign In  |  Register
Course List
  • CME Information

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Amgen.


R. Scott Wright, MD
Professor of Medicine
Mayo Clinic College of Medicine
Rochester, MN


Contracted Research: Astra Zeneca, Boehringer-Ingelheim, Pfizer, The Medicines Company

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY


Consulting Fee: Aegerion, Alexion, Akcea, Amarin, Amgen, Astra Zeneca, Gemphire, Invitae, Sanofi, Synageva
Speakers Bureau: Alexion, Amgen, Astra Zeneca, Genzyme, Invitae, Merck, Sanofi
Contracted Research: Aegerion, Gemphire, Pfizer

Alan S. Brown, MD, FACC, FAHA, FNLA
Director, Division of Cardiology
Advocate Heart Institute
Director, Midwest Heart Disease Prevention Center
Advocate Lutheran General Hospital 
Park Ridge, IL


Consulting Fee: Akcea, Amarin, Amgen, Kowa, Merck, Pfizer, Regeneron
Speakers Bureau: Amarin, Amgen, Merck, Regeneron, Sanofi

Christie M. Ballantyne, MD
Professor, Medicine & Genetics
Co-Director, Lipid Metab. & Atherosclerosis Clinic
Director, Atheroscler. Clin. Research Lab
Director, Ctr. for Cardiovascular Disease Prevention
Baylor College of Medicine & Methodist DeBakey Heart & Vasc. Ctr.
Houston, TX


Consulting Fee: Abbott Diagnostics, Amarin, Amgen, Astra Zeneca, Eli Lilly, Esperion, Genzyme, Ionis, Matinas BioPharma Inc, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo
Contracted Research: Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Otsuka, Regeneron, Roche Diagnostics, Sanofi-Synthelabo, Takeda, NIH, AHA, ADA


David Davidson, MD
Consulting Fees: Ideal Protein, Genzyme, WellPledge
Speakers Bureau: Amgen, Sanofi/Regeneron

Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™, 0.25 credits per video. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 25th, 2016 to August 24th, 2017.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the videos, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly for each video. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Even when using intensive statin monotherapy, many patients fail to achieve all of the desired lipid goals and remain at high residual risk of cardiovascular events. Lowering LDL-C is the primary focus of the management of dyslipidemia in patients with or at risk for cardiovascular disease. However, the American College of Cardiology and the American Heart Association published new guidelines that eliminated specific targets for LDL-C. Yet, all of the guidelines agree that lowering LDL-C levels is a key to lowering the risk for cardiovascular disease. Although statins do not completely remove risk, not all patients can tolerate them, and they are not sufficiently effective in patients with very high plasma levels of LDL-C, such as those with familial hypercholesterolemia or those with elevated plasma levels of lipoprotein(a). Recent advances in the understanding of lipoprotein metabolism have led to the development of the PCSK9 inhibitors and other therapies that lower LDL-C. This CME activity will feature interviews with clinical experts, who will discuss newly released evidence and guidelines regarding cardiovascular risk assessment, best practices when evaluating patients with elevated LDL-C, clinical study data pertaining to the effects of lowering LDL-C beyond evidence-based recommendations, and use of non-statin therapies for the treatment of dyslipidemia in patients who cannot achieve desired target levels.

Target Audience

The intended audience for the activities is cardiologists, endocrinologists, primary care physicians, family physicians, internists, and other health care professionals involved in the treatment of patients with dyslipidemia.

Learning Objectives

Upon successful completion of the video series, participants should be better able to:

  • Incorporate cardiovascular risk assessment, evidence-based guidelines, and best practices when evaluating patients with elevated LDL-C.
  • Assess clinical study data pertaining to the effect of lowering LDL-C beyond evidence-based recommendations and its effect on cardiovascular risk reduction.
  • Evaluate the use of non-statin therapies for the treatment of dyslipidemia in patients who are intolerant or in patients who cannot achieve desired target levels. Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.
  • Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved.

No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Educational Tools

For downloadable handouts, patient education tools, and online resources for your clinical practice provided by Vindico Medical Education, please visit:

CME Questions?

Contact us at or 856-994-9400, ext. 504.